Eprenetapopt has also been studied as a prophylactic post-transplant maintenance therapy in combination with azacitidine for patients with TP53-mutated AML and MDS leading a 1-year relapse-free survival of 58% (92). Here, TP53 is linked to acute myeloid leukemia.